2 is a steroid hormone best known for its role in calcium homeostasis. Its deficiency causes rickets in children and osteomalacia in adults. VD also regulates the proliferation and differentiation of normal and malignant cells of many tissue types. Because sunlight controls the first step of VD synthesis, namely, the photoconversion of 7-dehydrocholesterol to vitamin D 3 (1), the hormone is considered a "sun" medicine that is effective for the treatment and/or prevention of type II rickets, osteoporosis, autoimmune disorders, as well as epithelial cancers of many types.
Vitamin D 3 (VD)
2 is a steroid hormone best known for its role in calcium homeostasis. Its deficiency causes rickets in children and osteomalacia in adults. VD also regulates the proliferation and differentiation of normal and malignant cells of many tissue types. Because sunlight controls the first step of VD synthesis, namely, the photoconversion of 7-dehydrocholesterol to vitamin D 3 (1) , the hormone is considered a "sun" medicine that is effective for the treatment and/or prevention of type II rickets, osteoporosis, autoimmune disorders, as well as epithelial cancers of many types.
Ovarian cancer (OCa) is a fatal disease with an overall 5-year survival rate of about 40%. OCa mortality and incidence rates are lower in countries within 20 degrees of the equator (2) where there is a high amount of sunlight. In the United States, women between the ages of 45 and 54 living in the North have 5 times the OCa mortality rate of women living in Southern states (3) . The inverse correlation between sunlight exposure and OCa mortality indicates that decreased synthesis of VD may contribute to OCa initiation and/or progression. This idea has been further substantiated by recent studies (4 -7) showing that 1,25-dihydroxyvitamin D 3 (1,25-(OH) 2 D 3 ), the active form of VD, inhibits the growth of multiple OCa cell lines (4 -6) and OVCAR3 tumor xenografts in nude mice (7) .
Effects of VD are mediated through the vitamin D receptor (8) , which is a member of the steroid/thyroid receptor superfamily of ligand-regulated transcription factors. In response to the activation by 1,25-(OH) 2 D 3 , the receptor recruits multiple co-activators, including members of the p160 SRC family (9) , which are associated with histone acetyltransferase activity, and the DRIP complex (10) , which serves as a mediator between the vitamin D receptor and RNA polymerase II complex. Recent studies (11) have suggested that the anti-tumor activity of VD is mediated through its effect on gene transcription. In OCa cells, we have shown that the transcriptional up-regulation of GADD45 is essential for the 1,25-(OH) 2 D 3 -induced cell cycle arrest at the G 2 /M checkpoint (4). 1,25-(OH) 2 D 3 also increases p27 protein stability in OCa cells through down-regulation of Skp2 and cyclin E mRNA to induce cell cycle arrest at the G 1 /S checkpoint (6) . These studies suggest that the action of 1,25-(OH) 2 D 3 through the nuclear activation of vitamin D receptor is important for the anti-tumor activity of the hormone in OCa.
Because the anti-tumor activity of 1,25-(OH) 2 D 3 is mediated through regulation of gene expression, a more complete understanding of the mechanism underlying 1,25-(OH) 2 D 3 action in OCa cells necessitates identification of changes in gene expression induced by the hormone. In the present study, we profile transcriptional changes in OVCAR3 cells induced by 1,25-(OH) 2 D 3 using multiple independent microarray analyses. We concentrated our subsequent analysis to a few apoptosis-related genes from this list. Our studies reveal that 1,25-(OH) 2 D 3 regulates the expression of death receptors and protects cancer cells from apoptosis induced by death ligands. The findings suggest that a better understanding of both beneficial and adverse effects of 1,25-(OH) 2 D 3 in OCa cells is necessary for the development of effective OCa therapeutic strategies that utilize active VD compounds, either alone or in combination with other apoptosis-inducing agents. 2 D 3 was purchased from Calbiochem (La Jolla, CA). TRAIL, biological active Fas ligand, staurosporine, calcium ionophore A23187, and etoposide were from Sigma. The antibodies anti-TRAIL (BD Pharmingen), anti-TRAIL receptor 4 (TRAIL-R4), anti-Fas (Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-TRAIL-R2 (Oncogene Research Products, San Diego, CA), and anti-caspase-7 (Cell Signaling Technology Inc., Beverly, MA) were purchased commercially.
MATERIALS AND METHODS

Chemical Reagents, Antibodies, and Cell Cultures-1,25-(OH)
All cell lines used in the study have been described previously (6) . OVCAR3 cells were cultured in RPMI 1640 medium supplemented with 15% fetal bovine serum, 2 mM L-glutamine, penicillin (50 units/ml), streptomycin (50 g/ml), 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/liter glucose, 1.5 g/liter sodium bicarbonate, and 10 g/ml bovine insulin. Other cell lines were maintained in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum. For 1,25-(OH) 2 D 3 treatment, the hormone was dissolved in ethanol, diluted to the desired concentration in culturing medium, and added to the cells. For longer treatments, the medium was replaced with fresh medium containing 1,25-(OH) 2 Ethanol was included as vehicle controls, and all cells were exposed to the same amount of ethanol for the same length of time. Total RNA was extracted using TRIzol reagent (Invitrogen) and further purified using Qiagen RNeasy columns. An initial experiment was performed using the U95Av2 chip from Affymetrix Inc. (Santa Clara, CA). From this experiment it was determined that GADD45 expression changed in response to VD (4) . Three subsequent experiments were performed using the U133A chips (Affymetrix Inc.). In these experiments the response of the cells to 1,25-(OH) 2 D 3 was determined by Northern blotting analysis of GADD45 before using the isolated RNA for microarray analysis. The RNA samples were processed for hybridization to microarrays by the Microarray Core Facility of the H. Lee Moffitt Cancer Center. Briefly, RNA was converted to double-stranded cDNA using an oligo(dT) 24 primer containing a T7 promoter sequence. The resulting double-stranded cDNA was transcribed into biotin-labeled cRNA using T7 RNA polymerase. This cRNA was hybridized to GeneChip probe arrays. Unbound RNA was washed from the chips and the remaining biotinylated RNA was stained and the chips scanned. Scanned chip images were analyzed using microarray suite software (MAS 5.0) from Affymetrix. In total, four independent experiments were carried out.
Raw data were processed using Irizarry and Speed's Robust Multichip Analysis. After normalization, significance analysis of microarray (SAM) analysis (12) was performed by comparing gene expression profiles at time points of 8, 24, and 72 h to those of vehicle control (0 time point). Significant genes were clustered using GeneSpring software 6.0 (Silicon Genetics, Redwood City, CA). This resulted in groupings based on the general pattern of expression changes with time following 1,25-(OH) 2 D 3 addition. The final list of genes was then generated by evaluating each probeset from the SAM analysis for consistency. A gene was considered to be consistently regulated if the same gene expression profile was obtained in all three experiments performed with the U133A chips and detected by all probesets. Gene identification was based on the sequence of the probes used on the arrays (13) .
Reverse Transcription Polymerase Chain Reaction (RT-PCR)-RT-PCR was conducted according to the protocol of Invitrogen with minor modifications. Briefly, 1 g of pooled RNA from three independent experiments was reverse transcribed with the oligo(dT) 20 primer in a total reaction volume of 20 l. The amplification of target genes was carried out using 1 l of reverse transcription product in a total reaction volume of 25 l. PCR was performed using a GeneAmp PCR System 2700 (Applied Biosystem, Inc., Foster City, CA) for about 25 cycles with each cycle consisting of denaturing at 94°C for 30 s followed by annealing for 45 s at various temperatures (supplemental Table S1 ) and elongation for 1 min at 72°C. PCR products were visualized by electrophoresis on 1.5% agarose gels. Primers were synthesized by Invitrogen and the sequences are listed in supplemental Table S1 .
Immunoblotting Analysis, Cell Growth, and Apoptotic Assays-For immunoblotting analyses, cellular extracts were separated on SDS-PAGE gels and blotted onto nitrocellulose membranes. Antibodies were used at 1:500 to 1:1000 dilutions. Proteins were detected using ECL as described (6) .
To assay cell growth, methylthiazole tetrazolium (MTT) assays were performed as described (6) . For each data point, eight samples were analyzed in parallel. Absorption at 595 nm (A 595 nm ) was measured on a MRX microplate reader (DYNEX Technologies, Chantilly, VA).
The apoptotic index of cells treated with death ligands and 1,25-(OH) 2 D 3 was determined by flow cytometry following staining with Annexin V-fluorescein isothiocyanate and propidium iodide according to the manufacturer's protocol (Annexin V kit, Santa Cruz Biotechnology Inc.). Flow cytometry was performed in a BD Biosciences FACSCalibur flow cytometer. The data from 10,000 cells per time point were acquired and analyzed using CellQuest software. The apoptotic index of transfected cells was determined as previously described (6) . Transfected cells were fixed in 3.7% formaldehyde/phosphate-buffered saline and stained with 4Ј,6Ј-diamidino-2-phenylindole. The apoptotic index of green fluorescence protein (GFP)-positive cells was determined by scoring 400 GFP-positive cells in randomly selected microscopic fields for chromatin condensation and apoptotic body formation.
Caspase Assays-The activity of caspase-3 was determined by the amount of fluorescent AMC liberated from the cleavage of the peptide substrate, Ac-DEVD-AMC, specific for caspase-3, using an assay kit from BD Biosciences. AMC was measured using a spectrofluorometer at excitation of 380 nm and emission of 420 nm. Caspase-7 activity was similarly determined by the amount of free fluorescent AFC released from substrate, Ac-DEVD-AFC, by caspase-7 immunoprecipitates following the protocol of the assay kit from Cell Signaling (Beverly, MA). AFC fluorescence was measured at excitation of 400 nm and emission of 505 nm.
Plasmid, siRNA, and Transfection-TRAIL-R4 specific siRNA was synthesized from Upstate Inc. (Chicago, IL). The sense and antisense sequences were 5Ј-GGACAUGCAAAGGAAACAAtt-3Ј and 5Ј-UUGUUUCCUUUGCAUGUCCtt-3Ј, respectively. OVCAR3 cells were transfected with either pCMV-Fas and pEGFP or TRAIL-R4 siRNA using Lipofectamine or Oligofectamine according to the manufacturer's protocol (Invitrogen). pCMV plasmid and nonspecific siRNA were used as controls. Cells were pretreated with 10 Ϫ7 M 1,25-(OH) 2 D 3 or vehicle for 3 days before the transfection, then 6 h post-transfection, cells were replaced in fresh medium containing 1,25-(OH) 2 D 3 or vehicle. Fortyeight h later, cells were processed for immunoblotting analyses or treated with TRAIL or Fas ligand for apoptosis assays. (4) . To ensure the reproducibility of the microarray data, three independent analyses were subsequently performed with the U133A Affymetrix chips, which contain 22,283 probe sets and can be used to analyze the expression level of ϳ15,000 known human genes. For quality control, RNA samples were first tested by Northern blots for up-regulation of GADD45 to ensure that the cells from which the RNA was isolated had responded to the treatment (data not shown). Samples from cells treated with the hormone for 3 days were included to ensure that genes that are regulated by persistent 1,25-(OH) 2 D 3 treatment might be identified. These genes could mediate the anti-tumor activity of the hormone even though they may not be primary target genes. The raw data from the three microarray studies with U133A were first analyzed with SAM (12), a statistical method based on the conventional t test but developed specifically for microarray analysis. Using the 5% false discovery rate, we found that 710 probesets representing about 500 genes were modulated by 1,25-(OH) 2 D 3 . We reduced this list by requiring that a gene must change by at least 2.5-fold at one point during the time course of the experiment. The selected genes were clustered into groups using GeneSpring software, which generated five clusters ( Fig. 1) , of which, clusters 1 to 3 were up-regulated and clusters 4 and 5 were down-regulated. Genes in clusters 1 and 4 were induced or repressed at 8-or 24-h treatment and prolonged treatment did not change the fold regulation dramatically. Examples are GADD45 and 1,25-(OH) 2 D 3 24-hydroxylase genes, which both contain vitamin D response elements in their genome (4, 14) . Genes in clusters 2 and 5 were steadily up-or down-regulated and their fold regulation kept increasing as the time of treatment was extended. The cyclin A1 gene fell into cluster 3, which was repressed significantly at 8 h treatment but became induced at 72 h (2.58-fold) of 1,25-(OH) 2 D 3 treatment. The final gene list contains only those genes whose pattern of expression was consistent in all three experiments and across all probesets that detect the same gene. This reduced the list to 58 genes that appeared to be up-regulated (TABLE ONE) and 38 genes that appeared to be downregulated (TABLE TWO) . Many of these genes were also identified in (4, 6) . Except for 1,25-(OH) 2 D 3 24-hydroxylase that was increased by 55.91-fold, most of the genes were regulated modestly, possibly illustrating the fact that chronic treatment is required to induce a significant change in cell growth or suggesting that small changes in (20) . To identify genes that may mediate the apoptotic response, we incorporated apoptosis as a parameter in GeneSpring software and found 13 apoptosis-related genes that were significantly regulated as judged by SAM analysis using a 5% false discovery rate. This includes 5 up-regulated genes and 8 down-regulated genes (TABLE THREE) . Because fold change is an arbitrary parameter, we did not include this criterion when selecting apoptotic genes.
RESULTS
Identification of 1,25-(OH) 2 D 3 -regulated Genes by Microarray in OVCAR3 Cells
To confirm the regulation of the apoptosis-related genes by 1,25-(OH) 2 D 3 , RT-PCR analysis was performed with pooled RNA from three independent preparations. PCR analysis confirmed the regulation by 1,25-(OH) 2 D 3 of all 12 genes (Fig. 2) . We used GADD45 as a positive control in these experiments.
From the list of apoptotic genes, it is striking that multiple genes working on the extrinsic apoptotic pathway mediated through death receptors were regulated by 1,25-(OH) 2 D 3 . Fas, TRAIL receptor 2 (TRAIL-R2), and caspase-7 were down-regulated, whereas TRAIL and TRAIL-R4, a decoy receptor that suppresses the apoptosis response to TRAIL, were up-regulated. It thus appears that 1,25-(OH) 2 D 3 may regulate the extrinsic apoptotic pathway in OCa cells.
Before exploring ways to confirm the above prediction, we went further to determine whether the regulation of these genes by 1,25-(OH) 2 D 3 was manifested at the protein level (Fig. 3) . The immunoblotting analyses showed that TRAIL-R4 was induced, whereas Fas and caspase-7 proteins were repressed, which was consistent with the regulation seen at the RNA level. Conversely, the TRAIL protein appeared to be down-regulated and the protein level of TRAIL-R2 did not change. This demonstrates that regulation at the RNA level is not always manifested at the protein level. Overall, protein analyses support the prediction that 1,25-(OH) 2 D 3 may suppress the extrinsic apoptotic pathway mediated through death receptors. Fig. 4 , pretreatment with 1,25-(OH) 2 D 3 suppressed the decrease in cell numbers induced by TRAIL at various concentrations (Fig. 4A) or by 100 ng/ml at different time points (Fig. 4B) . More direct assessment of apoptosis markers reveals that the effects on cell loss are because of changes in the amount of induced apoptosis (Fig. 4, C-F) . Annexin V-positive cells are reduced by pretreatment with 1,25-(OH) 2 D 3 . In addition, the activation of caspase-7 (Fig. 4E ) and caspase-3 (Fig. 4F) by TRAIL was suppressed by the addition of 1,25-(OH) 2 D 3 . Caspase-7 was activated more dramatically by TRAIL (about 54-fold) than caspase-3 (about 5-fold), suggesting that caspase-7 may be preferentially involved in apoptosis induced by TRAIL. Caspase 7 is decreased by 1,25-(OH) 2 D 3 treatment, which may explain why 1,25-(OH) 2 D 3 treatment has a more dramatic effect on caspase 7 than on caspase 3. In addition, it seemed that the longer the 1,25-(OH) 2 D 3 pretreatment, the stronger was the resulting suppression.
The fact that Fas was down-regulated by 1,25-(OH) 2 D 3 suggests that protective action of 1,25-(OH) 2 D 3 may not be limited to apoptosis induced by TRAIL. Therefore, we also tested the effect of 1,25-(OH) 2 D 3 on Fas ligand-induced cytotoxicity in OVCAR3 cells. Similar to the above described TRAIL data, pretreatment with 1,25-(OH) 2 D 3 prevented the decrease in cell number induced by Fas ligand at various concentrations (Fig. 5A) or by 250 ng/ml Fas ligand at different time points (Fig. 5B) . Similar apoptotic analyses also confirmed that the protective hormonal effect on Fas ligand-induced toxicity in growth assays was because of the suppression of Fas ligand-induced apoptosis (Fig. 5,  C and D) .
To determine whether the suppressive effect of 1,25-(OH) 2 D 3 is universal to caspase-dependent apoptosis or restricted to the extrinsic death receptor pathway, we examined the effect of 1,25-(OH) 2 D 3 on cytotoxicity induced by different stimuli that are known to induce cell death through caspase-dependent apoptosis. This includes the protein kinase C inhibitor staurosporine and the calcium ionophore A23187. We observed that 1,25-(OH) 2 D 3 did not suppress staurosporine- (Fig.  5E ) or A23187 (Fig. 5F ) -induced apoptosis. Instead, 1,25-(OH) 2 D 3 pretreatment possibly enhanced staurosporine-or calcium ionophore A23187-induced apoptosis. This suggests that the protective effect is likely to be specific to the extrinsic apoptotic pathway mediated through death receptors.
Cell Specificity of the Protective Effect of 1,25-(OH) 2 D 3 on TRAILinduced Apoptosis-To determine whether the protective effect of 1,25-(OH) 2 D 3 against TRAIL-induced apoptosis is restricted to OVCAR3 cells, additional VD-sensitive OCa cells were sequentially treated with 1,25-(OH) 2 D 3 and TRAIL. As shown in Fig. 6, panel A, 1,25 -(OH) 2 D 3 exhibited detectable protection against TRAIL in the VD-sensitive cell lines 2008 and CAOV3. The protective effect was stronger in LNCaP prostate and MCF-7 breast cancer cells (Fig. 6A) . Thus, the protective To test whether this adverse effect of 1,25-(OH) 2 D 3 could be eliminated through manipulation of TRAIL-R4, we transiently transfected OVCAR3 cells with TRAIL-R4 siRNA to knockdown the expression of TRAIL-R4. As shown in Fig. 7 , panel A, TRAIL-R4 siRNA decreased the expression of TRAIL-R4 and its induction by 1,25-(OH) 2 D 3 . Consistent with decreased TRAIL-R4 expression, apoptosis induced by TRAIL was increased in the cells transfected with siRNA, and 1,25-(OH) 2 D 3 pretreatment no longer protected the cells from TRAIL-induced apoptosis (Fig. 7B) .
Conversely, we used an expression vector to increase the expression of Fas in 1,25-(OH) 2 D 3 -treated cells. As shown in Fig. 7C , the transfected cells expressed Fas at a much higher level than control cells and the down-regulation of Fas protein is no longer detectable because of dominance of the ectopic expression. After scoring the apoptotic index of the transfected cells (GFP-positive cells), it became clear that Fas (Fig. 7D) . These analyses show that molecular manipulation of death receptors is an effective strategy that may allow OCa patients to benefit from combined therapy with both 1,25-(OH) 2 D 3 and the ligands for death receptors.
DISCUSSION
The present study is the first to identify VD-targeted genes in OCa cells by large-scale profiling using microarray and represents an important step in our effort to understand the molecular mechanisms underlying VD action in OCa. Multiple aspects of the data are significant. First, a large number of genes were found to be regulated by 1,25-(OH) 2 D 3 . Most of these genes are reported here for the first time as 1,25-(OH) 2 D 3 -regulated. This large response provides an initial indication that cellular responses to VD treatment can be complex. Second, our identification of these genes is based on the analysis of multiple independent experiments. This gives us the ability to identify genes like TRAIL-R4, which was regulated modestly by 1,25-(OH) 2 D 3 . However, this regulation was confirmed at both the RNA and protein levels and caused a functional consequence in OCa. Third, and more importantly, we were able to validate the functional significance of the microarray data in OCa biology by demonstrating, with detailed molecular analyses, that the regulation of Fas and TRAIL receptors, detected by microarray, could be translated into the actual suppression of death ligand-induced apoptosis. These studies reveal an undesired effect of VD action in human cancer cells and provide a second indication that 1,25-(OH) 2 Table S2 ). Except the enzyme 24-hydroxylase, which processes 1,25-(OH) 2 D 3 , no other gene has been identified by more than three groups and only a few genes were commonly identified by two different groups. As pointed out by others (21, 25) , this probably reflects the fact that the action of 1,25-(OH) 2 D 3 in different cell lines involves different sets of genes. This emphasizes the necessity for study of VD-regulated genes in each cancer type on an individual basis. TABLES ONE and TWO contain genes encoding proteins involved in cell growth immunity, motility, cell-cell adhesion, and cell-extracellular matrix interactions. This implies that 1,25-(OH) 2 D 3 may influence many aspects of OCa cell homeostasis and could suppress OCa invasion and metastasis by regulating cellular processes in more ways than simple growth inhibition. Nonetheless, there are several genes on the list that have previously been associated with the growth or progression of OCa. For example, Edg2 has been implicated in growth inhibition (27) . Edg2 is one of the receptors for lysophosphatic acid, a potential biomarker for human OCa (28) . The induction of Edg2 by 1,25-(OH) 2 D 3 is likely to be directly involved in the hormone-induced suppression of OCa cell growth. The expression of CXC chemokines including interleukin-8, small inducible cytokine subfamily B6 (SCYB6), Gro-␤ and -␥ are down-regulated by 1,25-(OH) 2 D 3 . Interleukin-8 is a well documented stimulator of OCa growth and motility (29) . Down-regulation of interleukin-8 has been reported to contribute to the growth suppression of 1,25-(OH) 2 D 3 in skin cells (30) . It is possible that it also plays a role in OCa. Gro-␣ was recently shown to promote tumor growth, transformation, metastasis, and angiogenesis (31) , and the function of Gro-␤ and -␥ was assumed to be similar to Gro-␣ (32, 33) .
Our published studies suggest that cell death is an important mechanism of 1,25-(OH) 2 D 3 -induced growth suppression of OCa cells in vitro (20) and in nude mice (7) . Consistent with this observation was the fact that multiple apoptosis-related genes were found to be VD-regulated in the current microarray analysis (TABLE THREE) . VD up-regulated transforming growth factor-␤ and ABL1, known pro-apoptotic molecules (34, 35) , as well as GADD45, which is associated with apoptosis (36, 37) . Among down-regulated genes, API5-like 1 (API5L1) has been shown to be anti-apoptotic (38) and histone deacetylase 1 (HDAC1) controls the acetylation status of proapoptotic proteins such as p53 (39) . Inhibition of this HDAC activity induces apoptosis in cancer cells (40) . Counterintuitively, some genes that are implicated in promoting apoptosis, such as programmed cell death 4 (41, 42), cellular apoptosis susceptibility 1 (43) , and BCL2 adenovirus E1B 19-kDa interacting protein 2 (44), were down-regulated by 1,25-(OH) 2 D 3 (20) . It remains to be determined if these changes occur at the protein level and what role these changes play in OCa cells.
Anti-apoptotic actions of 1,25-(OH) 2 D 3 have been described in keratinocytes (45, 46) , osteoblasts (47) , lymphocytes (48) , thyrocytes (49) , and osteosarcoma cells (50) . The functions are consistent with the positive physiological role of 1,25-(OH) 2 D 3 in regulating the survival and differentiation of cells of skin, bone, and the immune system. However, it is striking that 1,25-(OH) 2 D 3 induces apoptosis in multiple human epithelial cancer cell types (51-53) but suppresses death receptor-mediated apoptosis. With respect to this point, it is important to point out that, although 3-day treatment with 1,25-(OH) 2 D 3 suppressed death receptor-mediated apoptosis, treatment with the hormone for longer than 6 days induced apoptosis by gradually decreasing the level of hTERT expression (20) . Besides, our data suggests that the 1,25-(OH) 2 D 3 induced suppression of apoptosis appears to be restricted to the extrinsic pathway because vitamin D exerted a synergistic effect with chemical agents such as staurosporine (Fig. 5) . Thus, therapy with active VD compounds alone or in combination with other chemical agents remains an attractive approach for the treatment of human OCa.
TRAIL is known to selectively induce apoptosis in transformed cells but not in normal cells. This unique property makes it a very attractive therapeutic agent for human cancers. The relief of the suppressive effect of 1,25-(OH) 2 D 3 on TRAIL-induced apoptosis by siRNA for TRAIL-R4 suggests that it may be beneficial to combine TRAIL-R4 siRNA, TRAIL, and 1,25-(OH) 2 D 3 for treatment of OCa. This is particularly important because 1,25-(OH) 2 D 3 -sensitive OCa cells appear to be also sensitive to TRAIL (Fig. 6 ). Because siRNA is being actively pursued as a novel approach for cancer therapy and suppression of TRAIL-induced apoptosis also occurs in prostate and breast cancer cells, the combination therapeutic concept proposed here for OCa is likely to be applicable to other 1,25-(OH) 2 D 3 -sensitive human cancers as well. 
